Deeper Dive into November 28 IPOs: Websites, Valuations, Backers, and Underwriters for REGE, LBRJ, PPHC, and FFLY
· Stocks · QuoteReporter
Deeper Dive into November 28 IPOs: Websites, Valuations, Backers, and Underwriters for REGE, LBRJ, PPHC, and FFLY
Building on our spotlight of this week’s IPO slate, here’s a more granular look at the four debuts slated for November 28: Regentis Biomaterials (REGE), Libera Gaming Operations (LBRJ), Public Policy Holding (PPHC), and FireFly Automatix (FFLY). We’ve sourced official websites, delved into valuations with comps, identified key underwriters and investors, and analyzed growth prospects, risks, and catalysts. With $104M+ on the line amid a post-Thanksgiving market thaw, these offer bites from biotech to agtech.
### 1. Regentis Biomaterials Ltd (REGE) – Nasdaq
**Official Website:** [www.regentis.co.il](https://www.regentis.co.il/)
Herzliya-based Regentis specializes in injectable hydrogels for orthopedic tissue repair, targeting the $10B+ cartilage regeneration market. Its GelrinC scaffold—degradable and minimally invasive—addresses knee osteoarthritis, affecting 32M Americans.
**Valuation Deep Dive:**
Seeking $7.2M via 1.8M shares at $4.00 (fixed price per filings), implying a ~$72M fully diluted market cap. This values Regentis at ~4x forward EV/revenue (projected $18M FY2026), a discount to peers like Organogenesis (6x) but premium to early-stage biotech averages (3x). Post-IPO cash (~$15M pro forma) funds pivotal trial completion (recruitment ends late 2025) and FDA PMA submission. Risks: 90%+ R&D burn rate ($69.8M H1 2025 loss); success hinges on Phase 3 data showing 70%+ pain reduction vs. microfracture. Catalysts: Positive topline in Q2 2026 could double valuation; comps suggest 2x pop on approval.
**Underwriters and Advisors:**
Lead: ThinkEquity (book-runner). No co-managers noted; legal counsel includes Israeli firm Goldfarb Seligman.
**Key Investors:**
Pre-IPO backers: Israel Biotech Fund, OrbiMed Advisors, SCP Vitalife, Royal DSM Ventures, Haisco Pharmaceutical, Technion Fund, ProSeed Ventures, Shalom Equity. Institutional ownership ~40%; no major U.S. names, but OrbiMed’s medtech track record adds credibility.
**Trading Start:** November 28, open market (9:30 AM ET); expect biotech volatility—watch for $5–$6 intraday if sentiment holds.
### 2. Libera Gaming Operations Inc (LBRJ) – NYSE American
**Official Website:** [libera-group.co.jp/en/](https://libera-group.co.jp/en/)
Tokyo’s Libera runs 11 pachinko parlors in Japan, tapping the $20B+ arcade gaming sector with electronic machines and loyalty tech. Founded 1965, it modernizes venues for 8M monthly players; FY2023 revenue $40.3M (+6% YoY), net $3.7M.
**Valuation Deep Dive:**
Aiming $7.5M through 1.5M–1.875M shares at $4.00–$5.00, yielding ~$75M–$94M cap. At midpoint ($4.50), ~0.2x trailing revenue—deep discount to MGM Resorts (1.5x) or Caesars (2x), reflecting micro-cap status and yen exposure. Profitable ops (9% margins) support 10–15% CAGR via digital upgrades; risks: Regulatory caps on machines (post-2022 reforms cut floors 20%), demographic decline (aging players). Catalysts: Online pachinko pivot could unlock $2B digital TAM; comps imply 50% upside on tourism rebound.
**Underwriters and Advisors:**
Joint book-runners: D. Boral Capital (ex-EF Hutton) and Sutter Securities. No co-managers; Japanese counsel via Mori Hamada & Matsumoto.
**Key Investors:**
Family offices and GREE Ventures (gaming VC); institutional float ~20% post-IPO. No marquee names, but local backers signal steady regional support.
**Trading Start:** November 28, NYSE open (9:30 AM ET); low-float debut may see 20–30% swings—position for yen strength.
### 3. Public Policy Holding Co Ltd (PPHC) – Nasdaq
**Official Website:** [pphcompany.com](https://pphcompany.com/)
D.C.-centric PPHC offers bipartisan lobbying and PR for Fortune 500 in health, finance, energy; 201 staff across U.S./UK/China/UAE. H1 2025 revenue $166M (+24% YoY); recent $33M TrailRunner buy bolsters crisis comms.
**Valuation Deep Dive:**
$60M via 4.1M shares at $14.64, ~$600M cap (~5x trailing P/E vs. FTI Consulting’s 15x). Uplisting from AIM uses proceeds for M&A (fifth since 2021); EBITDA $45M supports 20% growth, but $29.7M H1 loss flags integration costs. Risks: Geopolitical exposure (China ops 15% revenue); election cycles volatile. Catalysts: Atkins-era deregulation boosts advisory demand; 3–4% yield potential; comps eye $800M+ on Q4 beats.
**Underwriters and Advisors:**
Book-runners: Oppenheimer & Co., Canaccord Genuity, Texas Capital Securities. Legal: Cooley LLP (U.S.), Travers Smith (UK).
**Key Investors:**
AIM holders: BlackRock, Vanguard (~25% combined); post-IPO institutional ~40%. TrailRunner add-on drew policy VCs like New Mountain Capital.
**Trading Start:** November 28, Nasdaq open (9:30 AM ET); stable PR sector may limit pop—target $16–$18 on M&A news.
### 4. FireFly Automatix Inc (FFLY) – Nasdaq
**Official Website:** [fireflyautomatix.com](https://fireflyautomatix.com/)
Utah’s FireFly builds autonomous electric mowers for turf farms/golf; PATH harvesters and AMP robots (L100/X100) use AI for precision. FY2025 revenue $44M; 210 employees, 770+ units sold globally.
**Valuation Deep Dive:**
$29.5M through 4.5M–6.5M shares at $4.50–$6.50, ~$295M–$425M cap (~7x forward revenue vs. AppHarvest’s 5x). Funds scale production amid labor shortages; risks: Declining margins (from supply chain), John Deere competition. Catalysts: Nasdaq Robotics Index +25% YTD; international (Australia/Brazil) 30% revenue; 15–20% CAGR to $100M by 2028 implies 2x upside.
**Underwriters and Advisors:**
Joint book-runners: Roth Capital, Lake Street; co-manager: Chardan Capital Markets. Legal: Dorsey & Whitney.
**Key Investors:**
VCs: Eclipse Ventures, SOSV, Finistere Ventures, ATW Partners (~$21M raised). Post-IPO institutional ~30%; agtech funds eye sustainability angle.
**Trading Start:** November 28, Nasdaq open (9:30 AM ET); agtech hype could drive 40% debut pop—watch EV adoption metrics.
### Final Thoughts: A Mixed Bag for Year-End Plays
These IPOs blend speculative biotech/gaming with steady policy/agtech—total $104M signals rebound confidence. Valuations skew conservative (4–7x multiples), favoring growth stories amid Fed cuts. Risks: Holiday thin trading amplifies volatility; lock-ups expire May 2026. Retail via Robinhood; pros, comps suggest 20–50% pops. With $1T crypto wipeout fresh, these offer tangible bets.
—
**Disclaimer**
The content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments involve risks, and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting. MarketsFN.com and its authors are not liable for any losses or damages arising from your use of this information.
—